Linear growth and final height after treatment for Cushing's disease in childhood.

Cushing's disease is associated with growth failure in childhood and adolescence. Growth and final height were analyzed in 10 patients who were cured or in remission after treatment of Cushing's disease. Seven males and 3 females, aged 6.8-17.6 yr (bone age, 3.3-15.4 yr), had transsphenoid...

Full description

Bibliographic Details
Main Authors: Lebrethon, M, Grossman, AB, Afshar, F, Plowman, P, Besser, G, Savage, M
Format: Journal article
Language:English
Published: 2000
_version_ 1797060800996704256
author Lebrethon, M
Grossman, AB
Afshar, F
Plowman, P
Besser, G
Savage, M
author_facet Lebrethon, M
Grossman, AB
Afshar, F
Plowman, P
Besser, G
Savage, M
author_sort Lebrethon, M
collection OXFORD
description Cushing's disease is associated with growth failure in childhood and adolescence. Growth and final height were analyzed in 10 patients who were cured or in remission after treatment of Cushing's disease. Seven males and 3 females, aged 6.8-17.6 yr (bone age, 3.3-15.4 yr), had transsphenoidal surgery, which was combined with pituitary irradiation (4,500 cGy in 25 fractions) in 5 patients. At presentation, 5 patients were prepubertal (males), and 5 were pubertal (2 males and 3 females). The mean height SD score was -2.15 +/-1.26 (range, -0.21 to -4.32) compared with mean target height SD score of -0.43 +/- 0.58. Height velocity in 6 patients was subnormal (0.9-3.8 cm/yr). After treatment, short-term height velocity, over a mean interval of 0.57 yr, in 8 patients not receiving human GH (hGH) therapy, was variable (range, 0.8-7.6 cm/yr). GH stimulation tests (insulin tolerance test/glucagon) in 9 subjects showed peak GH levels of 0.5-20.9 mU/L. Eight were treated with hGH (14 IU/m2 wk), combined in 2 girls and 1 boy with a GnRH analog. After 1 yr of hGH, the mean height SD score had increased from -2.45 +/- 1.0 at initiation of hGH to -2.07 +/- 1.2 (P = 0.01). GH therapy was continued until final height or latest assessment. The mean final height SD score (n = 6) was - 1.24 +/- 1.38, and at the latest assessment the mean height SD score (n = 4) was - 1.52 +/- 1.33. Combining these 2 groups, the mean height so score was -1.36 +/- 1.29. The difference between final or latest height SD score and target height SD score was 0.93 +/- 1.13, i.e. less (P = 0.005) than the difference between height and target height SD score of 1.72 +/- 1.26 at presentation. In conclusion, catch-up and favorable long-term growth was seen after treatment for Cushing's disease. Posttreatment GH deficiency was frequent, and early hGH replacement may have contributed to the encouraging outcome.
first_indexed 2024-03-06T20:22:02Z
format Journal article
id oxford-uuid:2e2372dd-6a84-4375-b1cc-161419cf26d6
institution University of Oxford
language English
last_indexed 2024-03-06T20:22:02Z
publishDate 2000
record_format dspace
spelling oxford-uuid:2e2372dd-6a84-4375-b1cc-161419cf26d62022-03-26T12:47:09ZLinear growth and final height after treatment for Cushing's disease in childhood.Journal articlehttp://purl.org/coar/resource_type/c_dcae04bcuuid:2e2372dd-6a84-4375-b1cc-161419cf26d6EnglishSymplectic Elements at Oxford2000Lebrethon, MGrossman, ABAfshar, FPlowman, PBesser, GSavage, MCushing's disease is associated with growth failure in childhood and adolescence. Growth and final height were analyzed in 10 patients who were cured or in remission after treatment of Cushing's disease. Seven males and 3 females, aged 6.8-17.6 yr (bone age, 3.3-15.4 yr), had transsphenoidal surgery, which was combined with pituitary irradiation (4,500 cGy in 25 fractions) in 5 patients. At presentation, 5 patients were prepubertal (males), and 5 were pubertal (2 males and 3 females). The mean height SD score was -2.15 +/-1.26 (range, -0.21 to -4.32) compared with mean target height SD score of -0.43 +/- 0.58. Height velocity in 6 patients was subnormal (0.9-3.8 cm/yr). After treatment, short-term height velocity, over a mean interval of 0.57 yr, in 8 patients not receiving human GH (hGH) therapy, was variable (range, 0.8-7.6 cm/yr). GH stimulation tests (insulin tolerance test/glucagon) in 9 subjects showed peak GH levels of 0.5-20.9 mU/L. Eight were treated with hGH (14 IU/m2 wk), combined in 2 girls and 1 boy with a GnRH analog. After 1 yr of hGH, the mean height SD score had increased from -2.45 +/- 1.0 at initiation of hGH to -2.07 +/- 1.2 (P = 0.01). GH therapy was continued until final height or latest assessment. The mean final height SD score (n = 6) was - 1.24 +/- 1.38, and at the latest assessment the mean height SD score (n = 4) was - 1.52 +/- 1.33. Combining these 2 groups, the mean height so score was -1.36 +/- 1.29. The difference between final or latest height SD score and target height SD score was 0.93 +/- 1.13, i.e. less (P = 0.005) than the difference between height and target height SD score of 1.72 +/- 1.26 at presentation. In conclusion, catch-up and favorable long-term growth was seen after treatment for Cushing's disease. Posttreatment GH deficiency was frequent, and early hGH replacement may have contributed to the encouraging outcome.
spellingShingle Lebrethon, M
Grossman, AB
Afshar, F
Plowman, P
Besser, G
Savage, M
Linear growth and final height after treatment for Cushing's disease in childhood.
title Linear growth and final height after treatment for Cushing's disease in childhood.
title_full Linear growth and final height after treatment for Cushing's disease in childhood.
title_fullStr Linear growth and final height after treatment for Cushing's disease in childhood.
title_full_unstemmed Linear growth and final height after treatment for Cushing's disease in childhood.
title_short Linear growth and final height after treatment for Cushing's disease in childhood.
title_sort linear growth and final height after treatment for cushing s disease in childhood
work_keys_str_mv AT lebrethonm lineargrowthandfinalheightaftertreatmentforcushingsdiseaseinchildhood
AT grossmanab lineargrowthandfinalheightaftertreatmentforcushingsdiseaseinchildhood
AT afsharf lineargrowthandfinalheightaftertreatmentforcushingsdiseaseinchildhood
AT plowmanp lineargrowthandfinalheightaftertreatmentforcushingsdiseaseinchildhood
AT besserg lineargrowthandfinalheightaftertreatmentforcushingsdiseaseinchildhood
AT savagem lineargrowthandfinalheightaftertreatmentforcushingsdiseaseinchildhood